Using 19 AML samples with constitutive PI3K/AKT activation, the rapamycin-derivative inhibitor everolimus increased AKT phosphorylation by upregulating the expression of IRS-2 via an IGF-I/IGF-IR autocrine loop [58]. Here, AKT1 is linked to acute myeloid leukemia.